Filing Flows › 8-K events › Allarity Therapeutics
Allarity Therapeutics: termination of a material definitive agreement
Form 8-K filed Oct 30, 2026 · items 1.02
What the filing says
On October 28, 2026, Allarity Therapeutics, Inc. (the “Company”) terminated the Common Stock Purchase Agreement, dated January 28, 2026 (the “Purchase Agreement”), by and between the Company and Tumim Stone Capital LLC (“Tumim”), effective as of such date. As previously disclosed, the Purchase Agreement provided the Co
Read the filing on SEC EDGAR →
What usually followsAcross 2,368 8-Ks reporting Item 1.02 (termination of a material agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.5%, up 51% of the time); over the following 21 sessions, +1.1%. Every item ranked →
What this kind of filing means
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
Allarity Therapeutics at a glance
Allarity Therapeutics, Q1 2026: revenue $25K. The chart follows the revenue to costs, profit and cash.
Allarity Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Allarity Therapeutics’s other material 8-Ks
- Nov 2, 2026 — FDA decisions Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.